On October 29, 2025, Bio-Rad Laboratories reported third-quarter earnings with sales of US$653 million and a net loss of US$341.9 million, while also completing a major share repurchase and announcing ...

HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Alice N. Schwartz ...

Ascorbate peroxidases (APX) are class I heme-containing enzymes that convert hydrogen peroxide into water molecules. The gene encoding APX has been characterized in 11 strains of Trypanosoma cruzi ...

The global western blotting market is estimated at USD 2.01 billion in 2024 and is expected to grow to USD 2.13 billion in 2025 to reach approximately USD 3.6 billion by 2034, growing at a steady CAGR ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the appointment of ...

I rate Bio-Rad (BIO) with a buy rating. I start by mentioning that the low growth perspective is the negative aspect. For 2025, the company expects a 0.25% growth rate for its revenues, which might ...

Feb 19 (Reuters) - Diagnostics company Bio-Rad (BIO.N), opens new tab has been sued by the California Institute of Technology for allegedly misusing the school's patented technology for analyzing ...

Bio-Rad Laboratories, a Bay Area biotech giant best known for its diagnostic and research products, is laying off 5% of its staff — including more than 100 workers from its headquarters in Hercules.

Bio-Rad is filing fewer patents year after year, which suggests that it is struggling to innovate and develop new products and services. The company is lagging its peers with a negative ROE, and net ...

This study presents a valuable finding that pathways associated with ribosome biogenesis (RiBi) are activated during transition cell states and targeting ribosome biogenesis could be a viable approach ...